The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial
出版年份 2015 全文链接
标题
The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial
作者
关键词
-
出版物
CLINICAL INFECTIOUS DISEASES
Volume 61, Issue 3, Pages 403-408
出版商
Oxford University Press (OUP)
发表日期
2015-04-14
DOI
10.1093/cid/civ296
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?
- (2014) Andrew Hill et al. Journal of the International AIDS Society
- Lipid profile changes by high activity anti-retroviral therapy
- (2013) M. Duro et al. CLINICAL BIOCHEMISTRY
- Association of tenofovir exposure with kidney disease risk in HIV infection
- (2012) Rebecca Scherzer et al. AIDS
- Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents
- (2012) Roger Bedimo et al. AIDS
- Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles
- (2012) Georg Behrens et al. ANTIVIRAL THERAPY
- Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile
- (2012) José R. Santos et al. PLoS One
- Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202
- (2011) Grace A. McComsey et al. JOURNAL OF INFECTIOUS DISEASES
- A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206
- (2010) Marisa Tungsiripat et al. AIDS
- Rapid Improvement in Fasting Lipids and Hepatic Toxicity After Switching From Didanosine/Lamivudine to Tenofovir/Emtricitabine in Patients With Toxicity Attributable to Didanosine
- (2010) R. Palacios et al. HIV CLINICAL TRIALS
- Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients
- (2010) M. A. Valantin et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
- (2009) Roberto Ortiz et al. AIDS
- The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml
- (2009) Jose R Arribas et al. AIDS
- Improvements in Subcutaneous Fat, Lipid Profile, and Parameters of Mitochondrial Toxicity in Patients with Peripheral Lipoatrophy When Stavudine is Switched to Tenofovir (LIPOTEST Study)
- (2009) Esteban Ribera et al. HIV CLINICAL TRIALS
- Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients
- (2009) Jose R Arribas et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized Comparative Trial of Continued Zidovudine/Lamivudine or Replacement With Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated HIV-1-Infected Individuals
- (2009) Martin Fisher et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy
- (2008) J. Ananworanich et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now